Glycomics Platform


Leveraging the best global talent and technology

Synedgen has established an unrivaled, virtual drug discovery team.

Broad spectrum of expertise

With our highly experienced team of internal and external leaders, we can apply the platform broadly. We leverage in-house research, development and translational expertise with external thought leaders in particular disease areas to intelligently select targets.

Significant government partnerships

Synedgen has won competitive peer-reviewed grants from the following agencies:

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • National Institute of Dental and Craniofacial Research (NIDCR)
  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Cancer Institute (NCI)
  • National Heart, Lung and Blood Institute (NHLB)
  • U.S. Army Medical Research and Materiel Command (MRMC)
  • Defense Advanced Research Projects Agency (DARPA)

This non-dilutive capital has enabled development of our technology platform, the related IP and our extensive pipeline.

World expert academic partners

Synedgen works with national and international leaders in specific fields, wherein we can apply our technology platform.

Steve Sonis, DMD, DMSc

Dr. Steve Sonis is a senior surgeon at Brigham and Women’s Hospital specializing in oral medicine, Chief, Division of Oral Medicine, Surgery, Dana-Farber Cancer Institute, and is a Clinical Professor of Oral Medicine at the Harvard School of Dental Medicine. Dr. Sonis is actively involved in translational and clinical research in supportive cancer care, radiation-injury, and genomics. His research focuses on understanding the fundamental biological processes that lead to damage and inflammation at mucosal surfaces. His specific expertise is mucosal toxicities following cancer treatment regimens, identifying the genetic factors that predispose patients to toxicities, and developing and testing effective toxicity interventions. His research group has identified the biological pathways that are associated with injuries of the GI tract, skin, and lung, cancer regimen-related cognitive dysfunction and cancer-related fatigue.

Charles L. Hofacre, DVM, MAM, PhD

Dr. Charles Hofacre is the Director of Clinical Services, Poultry Diagnostic and Research Center, College of Veterinary Medicine at the University of Georgia. He is a recognized expert in the fields of clinical avian medicine, foodborne pathogens associated with poultry, and antibiotic resistant bacteria. He is an internationally recognized thought leader in the effects of antibiotic use in animals, the emergence of bacterial resistance, and the role of commensal bacterial in the health of the gastrointestinal tract. Dr. Hofacre serves on numerous national and international boards and committees, educating on antibacterial resistance and pathogen control advice.

Richard Tulli, MD, PhD

Richard Tuli, MD, PhD, is an attending radiation oncologist at Cedars-Sinai Medical Center and a Co-Director of the Pancreas Oncology Program at the Samuel Oschin Comprehensive Cancer Institute. His clinical and research interests are in gastrointestinal (GI) oncology, including investigating novel radiotherapy techniques to improve outcomes and minimize toxicity, and identifying radiosensitizing agents for treating cancer. He is active in developing the multidisciplinary management of GI cancer patients.